Dr. Ashok Kumar Vaid
Experience: Over 41 years
Medanta – The Medicity
Gurugram, India
Introduction
Dr. Ashok Kumar Vaid is Chairman of Medical Oncology, Hematology, and Stem Cell Transplant at Medanta Cancer Institute. Patients reach him for newly diagnosed cancers needing treatment planning, blood cancers requiring transplant, advanced tumors where genomic testing can find targeted drugs, and cases where previous treatment failed.
About Dr. Ashok Kumar Vaid
Dr. Ashok Kumar Vaid has been treating cancer for forty-one years. The Government of India gave him the Padma Shri in 2009 for what he’s done for oncology in this country. That kind of recognition doesn’t come easy. He completed his qualifications from both places, where he handled cancer volumes that most oncologists won’t encounter in a lifetime.
Dr. Ashok has built one of the largest and most successful stem cell transplant programs in the region from the ground up. He has been a principal investigator in over fifty international and national clinical trials, so patients sometimes get access to drugs not yet widely available. Previously headed oncology at Artemis Health Institute and was a senior consultant at Rajiv Gandhi Cancer Institute.
Qualifications
- MBBS — University of Jammu.
- MD (Internal Medicine) — University of Jammu.
- DM (Medical Oncology) — Tamil Nadu Dr. MGR Medical University, Chennai.
- Senior Residency — AIIMS, New Delhi.
Awards & Recognition
- Padma Shri (2009).
- Chikitsa Shiromani Award (2007).
- Performed the first 25 BMTs in the North Indian private sector.
- Principal investigator in over 50 clinical trials.
- Previously at Artemis and Rajiv Gandhi Cancer Institute.
- Founder member Indian Cooperative Oncology Network.
- NBE examiner and journal editorial board member.
- Member of ASCO, ESMO, and EHA.
Specialities & Expertise
- Bone Marrow Transplant
- Stem cell transplant
- Cancer genomics
- Precision oncology
- Immunotherapy
- CAR-T cell therapy
- Dendritic cell therapy
- Solid tumor chemotherapy
- Targeted therapy
Patient Experience & Approach
Patients say Dr. Vaid starts treatment after knowing exactly what mutation is driving the cancer before picking drugs. People enrolled in clinical trials through his practice appreciate getting access to newer drugs not yet available everywhere. Those coming for second opinions after failed treatment elsewhere say he reviewed everything from scratch and sometimes found targetable mutations the previous team never tested for.